Diagnosed with Influenza-induced AECOPD according to the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2025) and the Expert Consensus on the Diagnosis and Treatment of AECOPD in China (Updated 2023), confirmed by spirometry and viral testing (antigen or PCR), and excluding pneumonia and heart failure via chest CT and NT-proBNP.
Aged 60 years or older.
Voluntarily participate and provide written informed consent..
You may not be if
Known allergy or hypersensitivity to any component of the study medications.
Presence of severe bacterial co-infection at enrollment requiring systemic antibiotic therapy.
Severe dysfunction of major organs that may interfere with efficacy or safety assessment (e.g., severe cardiac insufficiency, hepatic impairment, or renal failure).
Participation in other interventional clinical trials within the past 3 months.
Inability to be contacted for follow-up (e.g., lack of permanent address or valid contact information).
Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation (e.g., severe cognitive impairment or psychiatric disorders).
Clareo Health | Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
